Get 40% Off
🎁 Free Gift Friday: Copy Legendary Investors' Portfolios in One ClickCopy for Free

Lixte Biotechnology Stock Surges on Positive Data

Published 01/06/2022, 03:32 AM
© Reuters.

By Sam Boughedda

Investing.com — Drug discovery firm Lixte Biotechnology Holdings Inc (NASDAQ:LIXT) saw its shares surge 62% on Wednesday after it revealed that its lead clinical compound, LB-100, increased the responsiveness of diverse cancers to immunotherapy in preclinical studies. 

According to Lixte, LB-100, a protein phosphatase (PP2A) inhibitor, was found by researchers in Taiwan to improve the success rate of anti-cancer immunotherapy.

"Recent advances in therapy with immune checkpoint inhibitors have been a true breakthrough in the development of more effective and less toxic treatment for many cancers," said Lixte's founder and CEO John Kovach.

"Unfortunately, most cancer patients do not respond to immunotherapy. There are widespread efforts to find pharmacologic and/or immunologic ways to turn unresponsive ('cold') tumors into responsive ('hot') tumors," he added.

Lixte shares more than doubled in the early part of the Wednesday session.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.